Q/C TECHNOLOGIES, INC. QCLS
Nasdaq · XNAS · stock · In Vitro & In Vivo Diagnostic Substances
Chart by TradingView
3/9
Piotroski F — financial health
-9.87
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | — | -$11.6M | — | — | $21.8M |
| 2024 | — | -$23.4M | — | — | $9.8M |
| 2023 | — | -$4.0M | — | — | $12.4M |
| 2022 | — | -$15.2M | — | — | $14.7M |
| 2021 | — | -$29.9M | — | — | $23.6M |
| 2020 | — | -$9.5M | — | — | -$5.3M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Silverman Joshua | Executive Chairman | 2026-04-13 | Grant | 162,162 | — |
| Voss Chelsea Sierra | director | 2026-03-30 | Buy | 1,753 | $3.15 |
| Voss Chelsea Sierra | director | 2026-01-16 | Grant | 212,500 | — |
| Voss Chelsea Sierra | director | 2026-01-16 | Grant | 25,000 | — |
| Glass Mitchell | Director, Chief Medical Off. | 2025-11-14 | Grant | 11,420 | — |
Why these scores methodology →
Piotroski F-score: 3/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: -9.87 (distress)
- Working capital / assets 0.268
- Retained earnings / assets -3.501
- EBIT / assets -0.239
- Equity / liabilities 1.323
Source: SEC EDGAR filings · CIK 0001321834 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.